Kairos Pharma (KAPA) news
Recent news
Kairos Pharma: 1-for-7 reverse stock split
Kairos Pharma Inc. (OTC: KPHR) has announced a 1-for-7 reverse stock split, effective as of the market open on August 22, 2026. The move is intended to comply with the minimum share price requirement set by the OTC Markets Group for continued listing [1]. The company stated that the reverse stock…
AInvest Wire · Aug 21, 2026Kairos Pharma announces strategic collaboration with Bayer to enhance Xofingo activity in metastatic prostate cancer
Kairos Pharma Inc. (NASDAQ: KPHM) has announced a strategic collaboration with Bayer AG to investigate the potential of Xofingo, its proprietary phosphatidylserine-targeting immunotherapy, in the treatment of metastatic prostate cancer. The partnership aims to evaluate the drug’s activity in…
AInvest Wire · Jul 22, 2026Kairos Pharma reports breakthrough interim safety data in Phase 1 trial of ENV-105 in EGFR-mutated lung cancer patients — targeting a $10 billion drug resistance market
AInvest Wire · Jul 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.